Navigation Links
January 1 Looms Large for Lymphoma Patients
Date:11/27/2007

Action necessary before year end to prevent loss of access to crucial

lymphoma drugs

WHITE PLAINS, Nov. 27 /PRNewswire/ -- The Leukemia & Lymphoma Society is urging the U.S. Department of Health and Human Services (HHS) to reverse detrimental changes to reimbursement rates for two lymphoma drugs. If the HHS does not act, the changes would severely limit the availability of the two therapies, which for thousands of non-Hodgkin lymphoma (NHL) patients represent their best or only resort for effective treatment.

The Centers for Medicare and Medicaid Services (CMS), an HHS division, has set reimbursement levels for these drugs, effective Jan. 1, which will create unreasonable obstacles to accessing these lifesaving therapies.

The drugs in jeopardy are two radioimmunotherapies -- Bexxar(R) and Zevalin(R) -- which are both critically important treatment options for patients with NHL. The drugs work by delivering a radioactive isotope to the cancer cells. CMS has established reimbursement levels for the 2008 hospital outpatient prospective payment system, which will result in less than 50 percent coverage for Bexxar and Zevalin. Hospitals will not be able to cover the other half of these costly drugs, thereby effectively eliminating access to these treatments.

The Society urges the following steps be taken immediately:

-- CMS should classify the radioimmunotherapy regimen a specified covered

patient drug. The Society believes that the CMS improperly considers

the initial doses of radioimmunotherapies to be diagnostic rather than

therapeutic doses. This is not consistent with U.S. Food and Drug

Administration labeling or with current practice.

-- CMS should cover the cost of compounding radioimmunotherapies.

Institutions should be paid fairly for the costs associated with

compounding these products.

-- The agency should consider setting payment for radioimmunotherapies on

the basis of 106 percent of average sales price or a composite

ambulatory payment classification that would reflect the entire costs

of the radioimmunotherapy regimen.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
3. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
4. Work time is the largest influence to the duration of a persons sleep
5. Large intensive care study reveals vital recommendations for treatment of brain injury patients
6. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
7. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
8. Preventing or reducing enlarged heart decreases risk of heart failure
9. A Place for Mom, Nations Largest Senior Care Referral Service, Fills a Gap in Employee Benefits
10. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
11. Worlds Largest Exhibit of Princess Dianas Dresses Hosted by Appleton Museum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The V Foundation for Cancer ... a Moment to Lose fundraising campaign. As the V Foundation’s boldest initiative to ... over cancer. The campaign aims to raise $200 million by 2020 and strategically ...
(Date:12/6/2016)... ... December 06, 2016 , ... Just in time for the holiday ... chocolate chip cookie recipe for Honeyville’s new Organic Quinoa Flour product for sale at ... in the near future. , “I think it’s wonderful that a growing number ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has announced ... on providing occupational safety and health training to public sector employees. , “The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... founder of Spectrum Science Communications , announced today that ... two consecutive years of high double digit growth in fee revenues. ... assumed management of the firm that Seng founded in 1996. Earlier ... of the Year and was selected among the Best Places to ... ...
Breaking Medicine Technology: